BRPI0915105A2 - composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer - Google Patents

composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer

Info

Publication number
BRPI0915105A2
BRPI0915105A2 BRPI0915105A BRPI0915105A BRPI0915105A2 BR PI0915105 A2 BRPI0915105 A2 BR PI0915105A2 BR PI0915105 A BRPI0915105 A BR PI0915105A BR PI0915105 A BRPI0915105 A BR PI0915105A BR PI0915105 A2 BRPI0915105 A2 BR PI0915105A2
Authority
BR
Brazil
Prior art keywords
biripidinyl
cancer
compound
treatment
heart failure
Prior art date
Application number
BRPI0915105A
Other languages
English (en)
Inventor
Rao Chang
Francis Jewell Charles Jr
Meredith Erik
G Gamber Gabriel
Miranda Karl
G Monovich Leuran
Dpietro Lucian
Paul Capparelli Michael
Soldermann Nicolas
Zhu Qingming
Burgis Robin
Yoon Taeyoung
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0915105A2 publication Critical patent/BRPI0915105A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0915105A 2008-06-13 2009-06-12 composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer BRPI0915105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6138408P 2008-06-13 2008-06-13
PCT/EP2009/057298 WO2009150230A1 (en) 2008-06-13 2009-06-12 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer

Publications (1)

Publication Number Publication Date
BRPI0915105A2 true BRPI0915105A2 (pt) 2019-09-24

Family

ID=40941599

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915105A BRPI0915105A2 (pt) 2008-06-13 2009-06-12 composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer

Country Status (11)

Country Link
US (1) US20110092505A1 (pt)
EP (1) EP2310381A1 (pt)
JP (1) JP2011522865A (pt)
KR (1) KR20110031318A (pt)
CN (1) CN102137856A (pt)
AU (1) AU2009256574A1 (pt)
BR (1) BRPI0915105A2 (pt)
CA (1) CA2727680A1 (pt)
EA (1) EA201100136A1 (pt)
MX (1) MX2010013773A (pt)
WO (1) WO2009150230A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307374B1 (en) * 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
DK2516434T3 (en) 2009-12-23 2015-08-31 Takeda Pharmaceutical FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS
US20130096160A1 (en) * 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
US8273142B2 (en) * 2010-09-02 2012-09-25 Cabot Microelectronics Corporation Silicon polishing compositions with high rate and low defectivity
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
CN103923085B (zh) * 2013-02-25 2016-08-24 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2016123151A1 (en) 2015-01-26 2016-08-04 University Of Washington Bumped kinase inhibitor compositions and methods for treating cancer
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Shp2の活性を阻害するための化合物および組成物
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
US11925628B2 (en) 2015-06-30 2024-03-12 Shanghai Jiao Tong University Applications for nicardipine in preparing anti-lung cancer products
AU2017283769B2 (en) 2016-06-14 2019-08-15 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
WO2018078083A1 (en) * 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
EP3568204B1 (en) 2017-01-10 2023-08-30 Novartis AG Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor
AU2019251360B2 (en) * 2018-04-10 2025-03-13 Neuropore Therapies, Inc. Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
MX2020013827A (es) 2018-06-22 2021-03-25 Bayer Ag Proceso de preparacion de compuestos triciclicos.
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
US12522606B2 (en) 2020-01-09 2026-01-13 University Of Washington Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy
CN112451529A (zh) * 2020-12-18 2021-03-09 忻佑康医药科技(南京)有限公司 Kb-NB 142-70的药物新用途
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
CN115449434B (zh) * 2022-10-13 2023-11-17 江西安邦药业有限公司 一种桉油连续分级精馏的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) * 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
AU2007245496A1 (en) * 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (AEAA) compounds and their use
CA2682340A1 (en) * 2007-04-06 2008-10-16 Novartis Ag [2 , 6] naphthyridines useful as protein kinase inhibitors

Also Published As

Publication number Publication date
CN102137856A (zh) 2011-07-27
WO2009150230A1 (en) 2009-12-17
AU2009256574A1 (en) 2009-12-17
KR20110031318A (ko) 2011-03-25
EA201100136A1 (ru) 2011-08-30
MX2010013773A (es) 2011-01-21
JP2011522865A (ja) 2011-08-04
CA2727680A1 (en) 2009-12-17
US20110092505A1 (en) 2011-04-21
EP2310381A1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
BRPI0812293A2 (pt) Derivados de 2-oxo-3-benzilbenzoxazol-2 -ona e compostos relacionados como inibidores de met quinase para o tratamento de tumores
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BRPI0915112A2 (pt) cateter de entalhe para tratar válvulas cardíacas doentes
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
EP2327448A4 (en) defibrillation catheter
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
BRPI0914555A2 (pt) derivados de triazol bicíclicos para o tratamento de tumores
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BR112012003372A2 (pt) vitamina d3 e análogos da mesma para o tratamento de alopecia.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.